Ryan Liu

RhoV Promotes Proliferation, Migration, and MAPK Activation in Pancreatic Ductal Adenocarcinoma

Shang Ru Wu, Jia Feng, Ting Wang, Ying Xin Xiao et autres

Abstract Background and Aims Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by diagnosis at advanced stages, limited therapeutic options, and frequent resistance to therapies. Although oncogenic KRAS mutations are central drivers of PDAC, alternative pathways indisputably contribute to its …

us, cn (code pays fourni par la source)

Targeting NRAS Inhibits Cancer Cell Growth and Enhances Paclitaxel Sensitivity in Lung Adenocarcinoma

Taoming Mo, Shuang Zhang, Qishuang Wei, Yali Zhang et autres

cn, us (code pays fourni par la source)

Targeting Nras Inhibits Cancer Cell Growth and Enhances Paclitaxel Sensitivity in Lung Adenocarcinoma

Taoming Mo, Shuang Zhang, Qishuang Wei, Yali Zhang et autres

cn, us (code pays fourni par la source)

Machine Learning of Single Cell Transcriptomic Data From anti-PD-1 Responders and Non-responders Reveals Distinct Resistance Mechanisms in Skin Cancers and PDAC

Ryan Liu, Emmanuel P. Dollinger, Qing Hua Nie

Immune checkpoint therapies such as PD-1 blockade have vastly improved the treatment of numerous cancers, including basal cell carcinoma (BCC). However, patients afflicted with pancreatic ductal carcinoma (PDAC), one of the deadliest malignancies, overwhelmingly exhibit negative responses to checkpoint therapy. We sought …

us (code pays fourni par la source)